Clinical Data Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug PharmaphorumBiogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.NeuroscienceRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial. Neuroscience Read full story Post navigation Previous: REGENXBIO slumps after serious side effects mar Duchenne gene therapy resultsNext: ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
